Feature Medifocus readies marketing expansion of Prolieve By Len Zehr Medifocus (OTCQX:MDFZF; TSX-V:MFS) is raising $6-million to $10-million to expand the sales and marketing of its minimally invasive Prolieve device as a treatment for benign prostatic hyperplasia (BPH), or... July 8, 2014